Correction.

Abstract

Journal of Clinical Pharmacy and TherapeuticsVolume 41, Issue 6 p. 741-741 ErratumFree Access Correction This article corrects the following: Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical indications P. J. Magin PhD FRACGP, S. Morgan MPH&TM FRACGP, A. Tapley MMedStat, C. McCowan PhD, L. Parkinson PhD, K. M. Henderson BNurs, C. Muth MD MPH, M. S. Hammer MSc, D. Pond PhD FRACGP, K. E. Mate PhD, N. A. Spike MBBS FRACGP, L. A. McArthur MBBS FRACGP FACRRM, M. L. Driel PhD FRACGP, Volume 41Issue 5Journal of Clinical Pharmacy and Therapeutics pages: 486-492 First Published online: June 27, 2016 First published: 27 October 2016 https://doi.org/10.1111/jcpt.12457AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Magin PJ, Morgan S, Tapley A, et al. Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical indications. J Clin Pharm Ther, 2016; doi: 10.1111/jcpt.12413.1 The authors wish to draw attention to the following error: In the Methods section of the manuscript ‘…medicines with anticholinergic effects were identified using the Anticholinergic Drug Scale (ADS) updated to reflect current Australian medicines availabilities (informed by AMH Australian Medicines Handbook, and a recent review)’. should read ‘…medicines with anticholinergic effects were identified using the Anticholinergic Drug Scale (ADS) updated to reflect current Australian medicines availabilities (informed by AMH Australian Medicines Handbook, and a recent review) and contemporary expert Australian opinion’. The correction reflects there having been, as well as an updating of the ADS, a process of expert review of the included medicines’ anticholinergic properties resulting in the exclusion of a number of medicines from the 2006 ADS. A post hoc analysis including the excluded medicines produced similar results to our original analysis: common prescription of anticholinergic medicines, anticholinergic burden driven mainly by less potent anticholinergics, the spectrum of indications for prescription varies across level of anticholinergic potency, and there is a resulting large contribution to anticholinergic medicines use of medicines not usually considered ‘anticholinergic’ and thus potentially not apparent to clinicians. A list of the drugs included and excluded from the original and revised analyses are available as an Appendix S1. The authors apologize for any inconvenience caused by this correction. Supporting Information Filename Description jcpt12457-sup-0001-AppendixS1.docWord document, 27 KB Appendix S1. Anticholinergic analyses – included and excluded medicines in the analyses. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Reference 1Magin PJ, Morgan S, Tapley A, et al. Anticholinergic medicines in an older primary care population: a cross-sectional analysis of medicines’ levels of anticholinergic activity and clinical indications. J Clin Pharm Ther, 2016; 41: 486– 492. Volume41, Issue6December 2016Pages 741-741 ReferencesRelatedInformation